VELOR
For laboratory research use only · Not for human consumption
Shop
LEAN

GLP2-TZ 20mg

20mg
$100.00
GLP2-TZ 20mg 20mg product photograph
1
17 available · Ships within 48 hours
Buy More & Save
Automatic volume pricing
1 Vial
$100.00
$100.00 / vial
2 Vials
$190.00
$95.00 / vialSave $10.00
4 Vials
$340.00
$85.00 / vialSave $60.00
  • Third-Party Tested
  • Cold-Chain Handled
  • Concierge Support

Questions about this compound, specifications, or documentation?

Speak with the Concierge

Established dual-agonist research compound referenced throughout published incretin receptor literature. Available in multiple research vial quantities.

  • Metabolic pathway research
  • Incretin-receptor biology
  • Cold-chain handled, third-party tested
VIEW BATCH COA
Independent lab verification · current batch
  • THIRD-PARTY TESTED
  • COLD-CHAIN HANDLED
  • TRACKED SHIPPING
  • QUALITY-FOCUSED SOURCING
SPECIFICATIONS
Product
GLP2-TZ 20mg
Strength
20mg
Vial Size
20mg per vial
SKU
VLR-TIRZ-20
Batch / Lot
Current batch listed on COA
Storage
Refrigerate 2–8°C · protect from light
Form
Lyophilized powder
RESEARCH USE ONLY

Sold strictly for laboratory and research purposes — never for human consumption, food, drug, or cosmetic use. 21+ only. A standard we hold ourselves to, not just the law.

EDUCATIONAL OVERVIEW

About this compound

Context, not noise — what the research actually says.

WHAT IT IS

A research-grade peptide investigated in metabolic pathway and incretin-receptor signaling literature.

LEAN
KEY BENEFITS
  • Studied across metabolic pathway signaling
  • Investigated in incretin-receptor biology
  • Referenced across published metabolic pathway literature
COMMON USES
  • Metabolic pathway research applications
  • Incretin-receptor biology studies
  • Pairs with adjacent pathway research compounds
THINGS TO KNOW
  • Lyophilized — requires reconstitution with BAC water
  • Store refrigerated at 36–46°F (2–8°C)
  • Research use only — not for human consumption
RELATED COLLECTION
Lean Research Collection

Pairs with Tesamorelin 10mg — Compounds referenced together in incretin and growth hormone axis literature.

VIEW COLLECTION
COLLECTION PRICE
$140.00
STORAGE

Cold-chain handling

REFRIGERATED
Store unopened at 36–46°F (2–8°C).
RECONSTITUTED
Keep refrigerated. Do not freeze.
PROTECT FROM LIGHT
Original packaging until use.

Store unopened vials refrigerated at 36–46°F (2–8°C). After reconstitution, keep refrigerated and use within the timeframe specified by your laboratory practice. Protect from light. Do not freeze reconstituted solution.

SHIPPING

Shipping information

Insulated, tracked, and handled with care from our facility to yours.

PROCESSING
Ships within 48 hours of order confirmation.
COLD-CHAIN
Insulated packaging with ice packs for temperature-sensitive compounds.
TRACKED & INSURED
Tracking provided. Domestic delivery typically 2–5 business days.

Local pickup is available by appointment for customers in the Phoenix, Arizona area. See the full shipping policy for details, accepted payment methods, and scheduling.

FAQ

Common questions

SCIENTIFIC RESEARCH OVERVIEW · SRO

Scientific Research Overview

A structured summary of published scientific literature on this compound — provided for educational reference only.

Metabolic Research
RESEARCH SNAPSHOT
Research Category
Investigational dual-incretin receptor agonist peptide
Biological Targets
  • GLP-1 receptor
  • GIP receptor
Primary Areas of Research
Glucose metabolism · Body weight regulation · Appetite signaling · Incretin-receptor biology · Cardiometabolic health · Adipose-tissue physiology
Current Stage of Research
Human Clinical Research
WHAT IS TIRZEPATIDE (GLP2-TZ)?

Tirzepatide (research designation GLP2-TZ) is a synthetic 39-amino-acid peptide studied in the scientific literature as a dual receptor agonist, engaging both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors within a single molecule. It is classified as a next-generation incretin-family research compound investigated for its effects on glucose metabolism, appetite signaling, and body-composition parameters.

PRIMARY AREAS OF RESEARCH
  • Glucose metabolism
  • Body weight regulation
  • Appetite signaling
  • Incretin-receptor biology
  • Cardiometabolic health
  • Adipose-tissue physiology

  • Published studies have investigated dual GIP and GLP-1 receptor agonism across multi-phase clinical trials in adults with type 2 diabetes and adults with obesity or overweight.
  • Research suggests dose-dependent reductions in HbA1c and fasting glucose across study cohorts investigated in the SURPASS program.
  • Current evidence indicates changes in body-weight-related parameters across study populations investigated in the SURMOUNT program.
  • Investigators have observed shifts in lipid-profile parameters, waist-circumference measurements, and markers of hepatic-fat content across published trial datasets.

Tirzepatide is being studied for its ability to simultaneously activate two incretin receptors. GLP-1 receptor activation is associated with glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central satiety signaling; GIP receptor activation is associated with post-nutrient insulin response, lipid handling in adipose tissue, and complementary appetite-related pathways. Current evidence indicates that co-engagement of GIP and GLP-1 receptors within a single molecule may produce a broader metabolic signaling profile than agonism at the GLP-1 receptor alone.
CURRENT AREAS OF INVESTIGATION
  • Metabolic Health
  • Glucose Metabolism
  • Appetite Regulation
  • Body Composition
  • Cardiometabolic Research
  • Incretin Biology

  1. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503–515. View source
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205–216. View source
  3. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143–155. View source
  4. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3–14. View source
  5. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;391(4):299–310. View source
RESEARCH STATUS

This compound continues to be investigated in preclinical and/or clinical research. Scientific understanding continues to evolve as additional studies are published.

RESEARCH DISCLAIMER

For laboratory research use only. This information summarizes published scientific literature for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.

RELATED · LEAN

More from this pillar

VIEW ALL
RESEARCH DISCLAIMER

All VELOR compounds are sold strictly for laboratory and research purposes only. They are not intended for human consumption, ingestion, or any food, drug, cosmetic, or therapeutic use. By purchasing, you confirm you are 21+ and a qualified researcher or research institution. Statements have not been evaluated by the FDA.

LEAN
GLP2-TZ 20mg
$100.00
1